1. Home
  2. KURA vs BJRI Comparison

KURA vs BJRI Comparison

Compare KURA & BJRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • BJRI
  • Stock Information
  • Founded
  • KURA 2014
  • BJRI 1978
  • Country
  • KURA United States
  • BJRI United States
  • Employees
  • KURA N/A
  • BJRI N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • BJRI Restaurants
  • Sector
  • KURA Health Care
  • BJRI Consumer Discretionary
  • Exchange
  • KURA Nasdaq
  • BJRI Nasdaq
  • Market Cap
  • KURA 793.2M
  • BJRI 837.4M
  • IPO Year
  • KURA N/A
  • BJRI 1996
  • Fundamental
  • Price
  • KURA $9.48
  • BJRI $36.70
  • Analyst Decision
  • KURA Strong Buy
  • BJRI Hold
  • Analyst Count
  • KURA 10
  • BJRI 7
  • Target Price
  • KURA $30.13
  • BJRI $37.50
  • AVG Volume (30 Days)
  • KURA 2.9M
  • BJRI 228.4K
  • Earning Date
  • KURA 11-07-2024
  • BJRI 02-13-2025
  • Dividend Yield
  • KURA N/A
  • BJRI N/A
  • EPS Growth
  • KURA N/A
  • BJRI 95.73
  • EPS
  • KURA N/A
  • BJRI 1.26
  • Revenue
  • KURA N/A
  • BJRI $1,336,598,000.00
  • Revenue This Year
  • KURA N/A
  • BJRI $3.13
  • Revenue Next Year
  • KURA $106.66
  • BJRI $3.35
  • P/E Ratio
  • KURA N/A
  • BJRI $29.34
  • Revenue Growth
  • KURA N/A
  • BJRI N/A
  • 52 Week Low
  • KURA $9.40
  • BJRI $27.61
  • 52 Week High
  • KURA $24.17
  • BJRI $38.87
  • Technical
  • Relative Strength Index (RSI)
  • KURA 24.01
  • BJRI 56.82
  • Support Level
  • KURA $9.40
  • BJRI $35.43
  • Resistance Level
  • KURA $10.02
  • BJRI $38.27
  • Average True Range (ATR)
  • KURA 0.46
  • BJRI 1.27
  • MACD
  • KURA 0.10
  • BJRI 0.02
  • Stochastic Oscillator
  • KURA 8.09
  • BJRI 64.82

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About BJRI BJ's Restaurants Inc.

BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in one operating segment that is casual dining company-owned restaurants. It has geographic presence only in the United States of America.

Share on Social Networks: